161 related articles for article (PubMed ID: 10213502)
1. Nitric oxide synthases catalyze the activation of redox cycling and bioreductive anticancer agents.
Garner AP; Paine MJ; Rodriguez-Crespo I; Chinje EC; Ortiz De Montellano P; Stratford IJ; Tew DG; Wolf CR
Cancer Res; 1999 Apr; 59(8):1929-34. PubMed ID: 10213502
[TBL] [Abstract][Full Text] [Related]
2. Non-nuclear localized human NOSII enhances the bioactivation and toxicity of tirapazamine (SR4233) in vitro.
Chinje EC; Cowen RL; Feng J; Sharma SP; Wind NS; Harris AL; Stratford IJ
Mol Pharmacol; 2003 Jun; 63(6):1248-55. PubMed ID: 12761334
[TBL] [Abstract][Full Text] [Related]
3. Exploiting the Inherent Photophysical Properties of the Major Tirapazamine Metabolite in the Development of Profluorescent Substrates for Enzymes That Catalyze the Bioreductive Activation of Hypoxia-Selective Anticancer Prodrugs.
Shen X; Laber CH; Sarkar U; Galazzi F; Johnson KM; Mahieu NG; Hillebrand R; Fuchs-Knotts T; Barnes CL; Baker GA; Gates KS
J Org Chem; 2018 Mar; 83(6):3126-3131. PubMed ID: 29461834
[TBL] [Abstract][Full Text] [Related]
4. Reduction of 3-amino-1,2,4-benzotriazine-1,4-di-N-oxide (tirapazamine, WIN 59075, SR 4233) to a DNA-damaging species: a direct role for NADPH:cytochrome P450 oxidoreductase.
Fitzsimmons SA; Lewis AD; Riley RJ; Workman P
Carcinogenesis; 1994 Aug; 15(8):1503-10. PubMed ID: 8055626
[TBL] [Abstract][Full Text] [Related]
5. Initial characterization of the major mouse cytochrome P450 enzymes involved in the reductive metabolism of the hypoxic cytotoxin 3-amino-1,2,4-benzotriazine-1,4-di-N-oxide (tirapazamine, SR 4233, WIN 59075).
Riley RJ; Hemingway SA; Graham MA; Workman P
Biochem Pharmacol; 1993 Mar; 45(5):1065-77. PubMed ID: 8461036
[TBL] [Abstract][Full Text] [Related]
6. Adaptation of human tumor cells to tirapazamine under aerobic conditions: implications of increased antioxidant enzyme activity to mechanism of aerobic cytotoxicity.
Elwell JH; Siim BG; Evans JW; Brown JM
Biochem Pharmacol; 1997 Jul; 54(2):249-57. PubMed ID: 9271329
[TBL] [Abstract][Full Text] [Related]
7. Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233).
Patterson AV; Barham HM; Chinje EC; Adams GE; Harris AL; Stratford IJ
Br J Cancer; 1995 Nov; 72(5):1144-50. PubMed ID: 7577460
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of DT-diaphorase (NAD(P)H:quinone oxidoreductase, EC 1.6.99.2) by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and flavone-8-acetic acid (FAA): implications for bioreductive drug development.
Phillips RM
Biochem Pharmacol; 1999 Jul; 58(2):303-10. PubMed ID: 10423172
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069.
Patterson AV; Saunders MP; Chinje EC; Talbot DC; Harris AL; Strafford IJ
Br J Cancer; 1997; 76(10):1338-47. PubMed ID: 9374381
[TBL] [Abstract][Full Text] [Related]
10. NADPH:cytochrome c (P450) reductase activates tirapazamine (SR4233) to restore hypoxic and oxic cytotoxicity in an aerobic resistant derivative of the A549 lung cancer cell line.
Saunders MP; Patterson AV; Chinje EC; Harris AL; Stratford IJ
Br J Cancer; 2000 Feb; 82(3):651-6. PubMed ID: 10682679
[TBL] [Abstract][Full Text] [Related]
11. The effect of functional groups on reduction and activation of quinone bioreductive agents by DT-diaphorase.
Fourie J; Oleschuk CJ; Guziec F; Guziec L; Fiterman DJ; Monterrosa C; Begleiter A
Cancer Chemother Pharmacol; 2002 Feb; 49(2):101-10. PubMed ID: 11862423
[TBL] [Abstract][Full Text] [Related]
12. Exploring vascular dysfunction caused by tirapazamine.
Huxham LA; Kyle AH; Baker JH; McNicol KL; Minchinton AI
Microvasc Res; 2008 Mar; 75(2):247-55. PubMed ID: 18023823
[TBL] [Abstract][Full Text] [Related]
13. 3-amino-1,2,4-benzotriazine 4-oxide: characterization of a new metabolite arising from bioreductive processing of the antitumor agent 3-amino-1,2,4-benzotriazine 1,4-dioxide (tirapazamine).
Fuchs T; Chowdhury G; Barnes CL; Gates KS
J Org Chem; 2001 Jan; 66(1):107-14. PubMed ID: 11429885
[TBL] [Abstract][Full Text] [Related]
14. Metabolism of tirapazamine by multiple reductases in the nucleus.
Delahoussaye YM; Evans JW; Brown JM
Biochem Pharmacol; 2001 Nov; 62(9):1201-9. PubMed ID: 11705453
[TBL] [Abstract][Full Text] [Related]
15. Effects of cytokine-induced macrophages on the response of tumor cells to banoxantrone (AQ4N).
Mehibel M; Singh S; Chinje EC; Cowen RL; Stratford IJ
Mol Cancer Ther; 2009 May; 8(5):1261-9. PubMed ID: 19435866
[TBL] [Abstract][Full Text] [Related]
16. Combination of the bioreductive drug tirapazamine with the chemotherapeutic prodrug cyclophosphamide for P450/P450-reductase-based cancer gene therapy.
Jounaidi Y; Waxman DJ
Cancer Res; 2000 Jul; 60(14):3761-9. PubMed ID: 10919648
[TBL] [Abstract][Full Text] [Related]
17. Metabolic activation of the antitumor drug 5-(Aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) by NO synthases.
Chandor A; Dijols S; Ramassamy B; Frapart Y; Mansuy D; Stuehr D; Helsby N; Boucher JL
Chem Res Toxicol; 2008 Apr; 21(4):836-43. PubMed ID: 18370414
[TBL] [Abstract][Full Text] [Related]
18. Reaction of the hypoxia-selective antitumor agent tirapazamine with a C1'-radical in single-stranded and double-stranded DNA: the drug and its metabolites can serve as surrogates for molecular oxygen in radical-mediated DNA damage reactions.
Hwang JT; Greenberg MM; Fuchs T; Gates KS
Biochemistry; 1999 Oct; 38(43):14248-55. PubMed ID: 10571998
[TBL] [Abstract][Full Text] [Related]
19. Tirapazamine has no Effect on Hepatotoxicity of Cisplatin and 5-fluorouracil but Interacts with Doxorubicin Leading to Side Changes in Redox Equilibrium.
Mandziuk S; Matysiak W; Korga A; Burdan F; Pasnik I; Hejna M; Korobowicz-Markiewicz A; Grzycka-Kowalczyk L; Kowalczyk M; Poleszak E; Jodlowska-Jedrych B; Dudka J
Basic Clin Pharmacol Toxicol; 2016 Sep; 119(3):330-40. PubMed ID: 26990033
[TBL] [Abstract][Full Text] [Related]
20. Direct measurement of pO2 distribution and bioreductive enzymes in human malignant brain tumors.
Rampling R; Cruickshank G; Lewis AD; Fitzsimmons SA; Workman P
Int J Radiat Oncol Biol Phys; 1994 Jun; 29(3):427-31. PubMed ID: 8005794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
